Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer.

Abstract

BACKGROUND:

Nanoparticle albumin-bound paclitaxel (nab-PTX), which avoids toxicities associated with a vehicle used in solvent-based PTX, has already shown safety and efficacy in patients with non-small cell lung cancer (NSCLC).

METHODS:

A phase II study was performed to assess the safety and efficacy of nab-PTX monotherapy as second-line chemotherapy after cytotoxic anticancer drugs for previously treated advanced NSCLC. Thirty-two patients with advanced NSCLC who had previously undergone 1 regimen of cytotoxic anticancer drugs were enrolled. Nab-PTX was administered intravenously at a dose of 100 mg/m on days 1, 8, and 15 of a 28-day cycle. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and toxicity profile were evaluated.

RESULTS:

The ORR was 28.1%, the DCR was 71.9%, median PFS was 3.9 months (95% confidence interval [CI] 2.7-5.1 months), and median OS was 10.9 months (95% CI 9.5-12.3 months). The mean relative dose intensity of nab-PTX was 77%. Grade 3 or 4 neutropenia, and grade 3 febrile neutropenia were observed in 11 and 1 of 32 patients, respectively. As nonhematologic toxicities, grade 3 peripheral sensory neuropathy and pneumonitis were each observed in 2 of 32 patients.

CONCLUSION:

Nab-PTX is an active and well-tolerated regimen in patients with previously treated NSCLC.

• Authors: Masaki Anzai, Miwa Morikawa, Takehiro Okuno, Yukihiro Umeda, Yoshiki Demura, Tomoaki Sonoda, Makiko Yamaguchi, Kiyoshi Kanno, Kohei Shiozaki, Shingo Ameshima, Masaya Akai, Tamotsu Ishizuka
• Journal: Medicine (Medicine (Baltimore)) Vol. 96 Issue 51 Pg. e9320 (Dec 2017) ISSN: 1536-5964 [Electronic] United States
• PMID: 29390506 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
• Copyright: Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Albumin-Bound Paclitaxel
• Antineoplastic Agents

Topics

• Aged
• Albumin-Bound Paclitaxel (therapeutic use)
• Anemia (chemically induced)
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, mortality)
• Female
• Humans
• Japan (epidemiology)
• Lung Neoplasms (drug therapy, mortality)
• Male
• Middle Aged
• Neutropenia (chemically induced)
• Peripheral Nervous System Diseases (chemically induced)
• Pneumonia (chemically induced)
• Salvage Therapy